Briumvi Európai Unió - magyar - EMA (European Medicines Agency)

briumvi

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Pedmarqsi Európai Unió - magyar - EMA (European Medicines Agency)

pedmarqsi

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - minden más terápiás készítmény - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.